Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of intratumoral toluenesulfonamide (pts) injection in stage iv driver gene-negative nsclc with/without chemoimmunotherapy

Conditions: Lung Cancer

Summary: the aim of this study was to evaluate the efficacy and safety of intratumoral injection of toluenesulfonamide(pts) in combination with or without first-line chemoimmunization based on standard treatment for stage iv driver gene-negative non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: 1. fully understand, be informed about the study and sign the informed consent form (icf); be willing to follow and be capable of completing all trial procedures； 2. age ≥18 years and ≤75 years at the time of signing the icf； 3. histologically or cytologically confirmed stage iv (ajcc 8th edition) driver gene negative non-small cell lung cancer； 4. at least one measurable target lesion assessed by the investigator according to the requirements of recist 1.1 within 4 weeks prior to enrollment, except for lesions proposed for percutaneous pts local injection； 5. localized injectable lesions located in a more confined area of the outer lung bands, less than or equal to 5 cm in diameter; these may be primary lesions that are not amenable to surgical resection or localized recurrent lesions after surgical resection and radiotherapy treatment； 6. ecog ps score of 0 or 1 within 7 days prior to local treatment tolerates pts intratumoral injections； 7. patients with localized lesions present and persistently stable (sd evaluated after two courses of treatment) after standard treatment with first-line chemoimmunotherapy； 8. life expectancy ≥ 3 months； 9. normal liver, kidney and heart function, normal blood routine, blood biochemistry, coagulation function and electrolytes and other physiological indicators. exclusion criteria: 1. plans for radiotherapy, surgery, etc. for the lesion after intratumor injection; 2. have severe cardiopulmonary dysfunction, advanced hepatic or renal insufficiency, malignant cardiac arrhythmia, hypertension, etc; 3. have severe bleeding, clotting disorders, infections, dehydration, etc; 4. have blood disorders, autoimmune diseases, cirrhosis of the liver, etc; 5. history of severe emphysema and pulmonary alveoli; 6. history of drug allergy or contraindication to toluene sulfonamide; 7. women who are pregnant, breastfeeding, or planning to become pregnant during the study period; 8. the investigators determined that the patients had other conditions that made them unsuitable for enrollment.
prospective single-timepoint huntington's disease biospecimen collection study

Conditions: Huntington Disease; Huntington's Dementia; Huntington Disease, Late Onset; Huntington; Dementia (Etiology)

Summary: objectives: the primary study objective is to collect blood from participants with huntington's disease in order to validate a ce marked cytosine, adenine, guanine (cag) assay for use in future studies for huntington's disease. the secondary study objective is to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and multi-omics profiling. the disease sample collection and analysis will be the foundation for an extensive network of biospecimen access and linked datasets for future translational research.

study design: * this protocol is a single-center, single-cohort, bioresearch study enrolling up to 5 participants. the cohort is as follows: o cohort 1: huntington's disease (n=5) * the study will enroll participants per the eligibility criteria. * participants will have 1 scheduled biospecimen collection visit(s). if the participant requires a recollection or is called for an extra sample donation, this will add additional volume and visit(s) to the collection schedule. the biospecimens collected from participants are whole blood. * the target blood volume of each phlebotomy visit will be 20 ml. the minimum accepted volume (in the event of tough venipuncture attempts or difficulty obtaining the blood) will be 5 ml. the maximum amount that can be drawn in a 6-week period will be 100 ml (whole blood 6-week maximum). * confirmation of eligibility and medical record review by a member of the study staff will be completed for participants of the cohort before they are considered fully enrolled.

Eligibility criteria:
cohort 1: huntington's disease inclusion: 1. the participant is willing and able to provide written informed consent 2. the participant is willing and able to provide appropriate photo identification 3. participants aged 25 to 65, inclusive 4. participants have been diagnosed with huntington's disease 5. patients must have numerical documentation of cag repeats present in the medical record, along with a huntington's disease diagnosis. 6. pre-existing evidence of cag repeats should be in the range of 40-60 repeats \*preference (not required for enrollment): patients to have different cag repeats from each other but this is not essential.\* exclusion: 1. participants who are pregnant or are nursing 2. participants with a known history of hiv, hepatitis, or other infectious diseases 3. participants who have taken an investigational product in the last 30 days 4. participants who have experienced excess blood loss, including blood donation, defined as 250 ml in the last month or 500 ml in the previous two months
optimal injection site for serratus anterior plane block in reconstructive breast surgery

Conditions: Pain, Postoperative

Summary: the novel introduction of various chest wall blocks such as the pecs i and ii/modified pecs blocks as well as the serratus anterior plane block have extended the application of perioperative regional anesthesia to provide analgesia for breast surgery. however, to our knowledge, there are no large studies that truly delineate the optimal injection site for the serratus anterior plane block.

analgesia for reconstructive breast surgery can be a challenging undertaking; these women have often been through painful mastectomy procedures coupled with the mental and physical discomfort of chemotherapy and its attendant side effects. additionally, the surgery itself can provoke significant pain; often requiring extensive dissection of soft tissue and muscle to provide flap coverage as well the real discomfort of tissue expansion. the literature has described 2 possible injection sites for the serratus anterior block, however, no study has defined optimal location based on analgesia and duration. patients will be randomized to receive a "deep" serratus anterior block (dsab) where local anesthetic is deposited deep to the serratus or a "superficial" serratus anterior block (ssab) where the local anesthetic is placed between serratus and latissimus dorsi. the investigator will then evaluate the difference based on pain scores, opiate consumption, length of hospital stay, as well as nausea and vomiting.

Eligibility criteria:
inclusion criteria: * patients undergoing reconstructive breast surgery exclusion criteria: * patients with allergies to the local anesthetic * patients who do no consent to regional anesthesia * patients in which serratus block would be contraindicated * patients whose anatomy preclude placement of the block

Keywords: deep serratus block reconstructive breast surgery superficial serratus block
vitamine d treatment in chronic heart failure

Conditions: Chronic Heart Failure; Vitamin D Adverse Reaction

Summary: the investigators hypothesized that in vitamin d deficiency the 25-oh-d3 vitamin substitution improve the heart function in chronic heart failure. type of study: controlled, randomized, double blind, placebo control number of patient: 300; 150 treated and 150 placebo controlled type of drug: 180 000 iu 25-oh-d3 vitamin oil (vigantol) per month in the 0,1,2,3,6, month duration of study:1+1 year primary end points: survival rate, ejection fraction by ultrasound, brain natriuretic peptid, secondary end points: safety of d-vitamin supplementation, well being score, blood pressure, bmi walking distant in 6 minutes visits: screening, randomization, 1month, 2 month, 3 month, 6 month, 12 month, 24 month,


Eligibility criteria:
inclusion criteria: * nyha ii-iv * vitamin d level between 10-30 ng/ml * ejection fraction by ultrasound \< 40 % exclusion criteria: * blood calcium \> 2,6 mmol/l * urinary calcium \> 0,1 mmol/body weight kg/die * blood phosphorus \> 1,45 mmol/l * nephrolithiasis in the history * gfr \< 30 ml/min * vitamin d injection in the last 6 month * actual 1,25-oh2-d3 vitamin treatment * myocardial infarction or serious coronaria stenosis in the anamnesis uncontrolled atrial fibrillation * serious valve disease

Keywords: vitamin d heart failure
perfluorooctyl bromide which empowers the liquid to flat the detached retina and displace the underneath fluids anteriorly

Conditions: Retinal Disease

Summary: perfluorohexyloctaneis essential for repositioning giant retinal breaks and can be used for removal of subretinal fluid as well as stabilization of the retina to offset


Eligibility criteria:
inclusion criteria: * - is 20 years or older has been diagnosed with keratoconus; has no other active ocular disease; is not pregnant or nursing; exclusion criteria: * is under the age of 20 has best corrected visual acuity outside 20/400; pregnant or nursing at the time of enrollment in the study;
alveolar and serum srage in severe asthma in children

Conditions: Asthma in Children

Summary: srage is a recognized marker of alveolar injury in acute respiratory distress syndrome (ards). more recently, it seems to be an interesting marker in asthma. it is the soluble form of the pro-inflammatory rage receptor overexpressed in the lungs and in particular the bronchi. it acts as a decoy to its ligands, and thus blocks the pro-inflammatory axis of rage. few studies are available in asthma, especially in children. a local study showed low levels of serum srage in the context of acute bronchiolitis. the same finding emerges from the few studies available in asthma, with rates all the lower when the asthma is poorly controlled. a study carried out in the animal model in 2012 found an absence of inflammatory infiltrate, the absence of increased expression of mucin and the absence of mucus goblet cell hyperplasia within the respiratory epithelium in the absence of rage receptor in sensitized mice dust mites, after exposure to their allergen. one could imagine in the long term a potential therapeutic avenue by a substitution in srage in this pathology. the objective of this study is to study the ability of the alveolar srage level measured on broncho-alveolar lavage for assessment, to discriminate the clinical degrees of control of severe asthma in children.


Eligibility criteria:
inclusion criteria: * severe asthma * weight greater than or equal to 5 kg exclusion criteria: * current respiratory infection * bronchopulmonary dysplasia or prematurity \< 34 weeks * diffuse infiltrative pneumonia * cystic fibrosis, primary ciliary dyskinesia * known immune deficiencies; * congenital heart disease; * cardiomyopathy; * ongoing pericarditis, myopericarditis, endocarditis; * chronic valvular pathology; * known autoimmune disease; * neuromuscular pathology;

Keywords: soluble receptor for advanced glycation end products inflammation
manipulative therapy techniques to treat chronic low back pain

Conditions: Low Back Pain; Chronic Disease

Summary: the purpose of this study is to analyze the effectiveness of a three manipulative therapy techniques in people with chronic low back pain.

objective: to analyze the effectiveness of a three manipulative therapy techniques in individuals with chronic non-specific low back pain of mechanical etiology. design: randomized clinical trial. setting: almeria, south spain. participants: sixty two with chronic non-specific low back pain will be randomly assigned to an experimental or control group. intervention: for 3-week, the experimental group will undergo treatment comprising 3 sessions (1/week) of manipulative therapy techniques in the lumbar and sacral areas, and the control group will receive a functional technique in the lumbar area. main outcome measures: oswestry disability index, pain visual analogue scale, tampa scale for kinesiophobia, roland-morris disability questionnaire, mcquade test, quality of life scores and the range of trunk anteflexion motion, which were all assessed before the treatment and immediately after the last treatment session. the primary outcome measure is the change in the rmdq score at the end of the 3 weeks study period. a difference of 2.5 point is considered to be the minimum clinically important difference in the rmdq score. a sample size of 62 patients (31 per group) would enable detection of a 2.5 point difference between groups given 80-90% power, a 5% (two-tailed) significance level, and a conservative standard derivation of 5 points. key baseline demographic variables and clinical measure scores will be compared between groups by using independent student t tests for continuous data and chi-square tests for categorical data. separate 2x2 mixed model anova with repeated measurements for the time factor need to be conducted in order to test between-groups differences in visual analogue scale, mcquade test, range of trunk anteflexion motion, oswestry disability index, roland morris disability questionnaire, tampa scale for kinesiophobia, and quality of life as the dependent variables, with group (functional technique or three manipulative therapy techniques) as the between subjects variable and time (baseline, post-treatment). a paired t-test will perform to test within-group differences in score changes from pre- to post-treatment. effect size will test using cohen's d. p = 0.05 will be considered significant in all tests.

Eligibility criteria:
inclusion criteria: * low back pain for ≥ 3 months. * score ≥4 on the roland morris disability questionnaire. * no undergoing another physical therapy treatment. * inability to achieve lumbar muscle flexion-relaxation in trunk flexion exclusion criteria: * clinical signs of radiculopathy. * presence of lumbar stenosis. * fibromyalgia. * spondylolisthesis. * history of spinal surgery. * treatment with corticosteroids in the past two weeks. * disease of the central or peripheral nervous system.

Keywords: low back pain. manipulative therapy techniques. randomized controlled trial. chronic pain.
cyclophotocoagulation in primary open angle glaucoma

Conditions: Primary Open Angle Glaucoma

Summary: the use of cyclodestruction procedures has been extended to patients with non-refractory glaucoma and good vision. our aim is to compare the safety and efﬁcacy of three cyclodestructive treatments; high intensity focused ultrasound (hifu) cyclocoagulation versus micropulse cyclophotocoagulation (mp-cpc) versus transscleral continuous wave cyclophotocoagulation (cw-cpc) for the treatment of primary open angle glaucoma.


Eligibility criteria:
inclusion criteria: * medically uncontrolled, primary open angle glaucoma attending glaucoma clinic exclusion criteria: * patients with history of previous laser or surgical intervention
chronic granulomatous disease study in china

Conditions: Granulomatous Disease, Chronic

Summary: cgd is a rare inherited primary immunodeficiency which is caused by the defect in one of the subunits of nadph oxidase complex.we tend to collect and analyze chinese cgd patients who are diagnosed in hospitals affiliated to shanghai jiao tong university school of medicine, including clinical feature, laboratory data and genetic information. we aim to find out clinical, distribution, genetic characteristic of cgd in chinese population, etc., thus further improving the level of diagnosis and treatment for cgd.


Eligibility criteria:
inclusion criteria: * x-linked and ar-linked chronic granulomatous disease * history of life-threatening severe infections * a functional assay demonstrating abnormal nadph oxidase function or clinical history consistent with cgd exclusion criteria: * presence of other primary immunodeficiency syndromes that do not meet the clinical and laboratory criteria for cgd.
prevention of infection in indian neonates - phase ii probiotics study

Conditions: Sepsis

Summary: india, with one of the world's largest populations, continues to struggle with extremely high infant and neonatal mortality rates. neonatal infection (sepsis) now accounts for 50 percent of deaths among community-born (and 20 percent of mortality among hospital-born) infants. this study is the first phase of a multi-phase project investigating interventions to prevent neonatal infection in india.

phase ii is a hospital based intervention (n = 297 infants) measuring the colonizing ability, safety, and tolerance of a probiotic supplement, lactobacillus plantarum in the neonatal gut. newborn infants ≥ 35 weeks of gestation will be randomized to receive either l. plantarum preparations (containing 109 organisms) or placebo preparations orally once a day for the first 7 days of life. the final stage of the project will be a community-based randomized double-blind placebo-controlled trial of l. plantarum enrolling over 8,000 newborns to examine the efficacy of probiotic supplementation in reducing neonatal infection in indian neonates.

Eligibility criteria:
inclusion criteria: * infants ≥ 35 weeks and ≥1800g born in the hospital * infants \> 12 hours and \< 72 hours of age at enrollment * infants likely to be hospitalized for 5-7 days without antibiotic treatment * informed consent by one parent or guardian * infants begun breastfeeding exclusion criteria: * antibiotic therapy prior to enrollment * evidence or suspicion of clinical sepsis before randomization * inability (as determined by the physician) to tolerate oral feeding of study supplement * presence of major congenital anomalies * infant's home is \>30km away from hospital a major congenital anomaly is defined as any malformation that is felt to be life-threatening or that requires surgical intervention. if the medical officer is uncertain whether an anomaly is life-threatening, he/she should not enroll the infant.

Keywords: neonatal sepsis global network probiotics india international maternal and child health
observation study an immunogenicity modified trc-id regimen with cprv with or without rabies immunoglobulin in children

Conditions: Dog Bite

Summary: to determine immunogenicity and safety study of modified trc-id regimen with a new chromatographically purified vero cell rabies vaccine (speeda®) as post exposure rabies intradermal regimen with or without rabies immunoglobulin in children

post exposure rabies vaccination with modified thai red cross intrademal regimen has been proven to be immunogenic and effection when using purified vero cell vaccine (pvrv) in present, new chromatographically purified vero cell rabies vaccine (speeda), chromatography purifed vero cell derived rabies vaccine, is manufactured by the liaoning chengda biotechnology is available this study has a goal to determine the immunogenicity of speeda when using with post exposure rabies intradermal vaccination with or without rabies immune globulin in children

Eligibility criteria:
inclusion criteria: * they are 1-15 years healthy children * give signed informed consent from their parents * willing to participate in this study and be able to receive the vaccination and collect blood sample as the study plan. exclusion criteria: * they have prior history of rabies vaccination or any equine/human serum administration such as snake antivenom and tetanus antiserum or vaccine allergy * persons who have immunosuppressive conditions such as known hiv infection, transplantation, chronic renal failure, receiving of steroid or immunosuppressive drugs * person received anti-malarial drugs within the previous two months or any blood products within previous three months were excluded * urine pregnancy test must be done in all female adolescents to exclude the pregnancy in first visit

Keywords: rabies modified trc intradermal rabies vaccine speeda
effect of acupuncture on inflammation and immune function after craniotomy

Conditions: Unruptured Cerebral Aneurysm; Hemifacial Spasm; Brain Tumor

Summary: the aim of this study is to evaluate the effect of acupuncture on inflammation and immune function after craniotomy. this study will be a single-center, parallel group clinical trial that will be conducted at kyung hee university hospital at gangdong, seoul, korea.

for study group, the intervention will start no more than 48 hours after craniotomy and will be given once a day for 6 days (a total of 6 sessions within 8 days). acupuncture, electroacupuncture, and intradermal acupuncture will be performed at every session. for control group, the subjects in the control group will only receive conventional treatment.

Eligibility criteria:
inclusion criteria: participants must meet all of the following criteria in order to be included: 1. planning to undergo regular craniotomy performed for an unruptured aneurysm, facial spasm, or brain tumor; 2. age \> 18 years; 3. acupuncture treatment that can start within 48 h after craniotomy; 4. voluntary participation and provision of signed informed consent form. exclusion criteria: participants with any of the following conditions will be excluded: 1. serum c-reactive protein (crp) level ≥ 1.0 mg/dl before craniotomy; 2. a condition other than an unruptured aneurysm, facial spasm, or brain tumor as an indication for craniotomy; 3. craniotomy performed for infectious brain diseases such as brain abscess or subdural empyema; 4. medication use that can affect the immune system or white blood cell (wbc) count, such as immunosuppressive drugs, steroids, or anticancer drugs or use of these medications within one month prior to the craniotomy; 5. a history of surgery at the same site; 6. emergency surgery; or 7. a severe medical disease, e.g. congestive heart failure, chronic renal failure.